# Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

Source: https://onco.cc/trials/nct07745361/  
OnCo record `nct07745361` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Apalutamide in prostate cancer, run by Monte Rosa Therapeutics, Inc, now recruiting.

## Summary

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer is a phase 2 interventional study registered as NCT07745361 by Monte Rosa Therapeutics, Inc, with 25 participants planned, started 2026-08 and due to reach its primary completion in 2027-10. Interventions recorded: Oral MRT-2359, Apalutamide. Conditions listed: Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07745361
- Phase: 2
- Setting: MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer
- Sponsor: Monte Rosa Therapeutics, Inc
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT07745361: https://clinicaltrials.gov/study/NCT07745361

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Apalutamide](https://onco.cc/drugs/apalutamide/)
- companies: [Monte Rosa Therapeutics](https://onco.cc/companies/monte-rosa/)

---
JSON: https://onco.cc/api/v1/entities/nct07745361.json